Kriya Therapeutics, Inc.

Kriya Therapeutics is a biopharmaceutical company focused on developing gene therapies for common diseases that affect millions of people worldwide. Their mission is to make gene therapies accessible and affordable for everyone who needs them. Kriya’s pipeline includes several one-time gene therapies targeting a variety of diseases across ophthalmology, metabolic disease, and neurology, with a particular focus on areas of high unmet need. They are committed to innovation, employing cutting-edge research and computational biology to develop their gene therapies.

Kriya's strategy is to deliver gene therapies directly to the target tissue, using validated biological pathways and de-risked clinical and regulatory paths. They also prioritize the development of scalable manufacturing processes that will ultimately make gene therapies more affordable for a wider range of patients. With a strong leadership team and a robust pipeline, Kriya is positioned to be a major player in the future of gene therapy.

Kriya Therapeutics is a biopharmaceutical company dedicated to revolutionizing medicine by developing life-changing gene therapies for common diseases that affect millions worldwide. They strive to make these therapies accessible to a broad patient population, with a mission to eliminate human suffering and enable people to live without the burden of disease. Their goal is to create a world where gene therapy is not just for the few, but for the many in need.

Kriya Therapeutics fosters a culture that values collaboration, innovation, and leadership. They emphasize open communication, sharing ideas, and engaging in respectful debate. The company encourages employees to think creatively and challenge the status quo while remaining focused on their mission of developing accessible gene therapies. They also promote a culture of accountability and ambition, encouraging employees to go the extra mile and strive for excellence.